ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsis

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsis

All resolutions submitted for a vote at today’s Combined General Meeting were approved

Launch of the largest pivotal clinical trial for CER-001 in sepsis, the 3rd cause of death worldwide

Progress in regulatory and manufacturing phases toward approval of CER-001 for LCAT deficiency

Financial visibility through the end of 2028 following the raising of up to €33 million